Pfizer Inc. has entered into a definitive agreement to acquire Metsera Inc., a clinical-stage biopharmaceutical company focused on obesity and cardiometabolic diseases, for approximately $4.9 billion. The deal, unanimously approved by the Boards of Directors of both companies, includes a
An analysis of the CDMOs operating facilities in Europe, by Small Molecule, Biologics and Cell & Gene Therapty
Novartis has built up substantial pharmaceutical stockpiles in the United States and announced major manufacturing investments as the Swiss company prepares for potential tariffs under President Trump’s trade policies, CEO Vas Narasimhan revealed on Saturday. Speaking to Swiss newspaper Neue
Navin Moleculor has appointed Dr. Vijay Kaiwar as CEO-CDMO, effective 25 August 2025, with the formal assumption of duties on 21 September 2025. Based at Dewas, he will report to Managing Director, Mr. Nitin Kulkarni. Dr. Kaiwar brings more than
“A strategic partnerships is not a transactional relationship – it’s a partnership that should last. If we incentivise through co-investments and risk sharing, the partner can grow their business while enabling us to achieve cost and volume targets.” – Shilpi
PolyPeptide Group AG has reached a key milestone in its Malmö, Sweden expansion by completing the delivery and installation of pre-built modules at the site. The development is part of a modular construction project announced in January 2025, which aims
AGC Pharma Chemicals has inaugurated the €110 million expansion of its factory in Malgrat de Mar, Barcelona. The investment, which exceeded the initially announced €90 million, was completed one year later than scheduled. The company stated that the new facilities
Merck has officially inaugurated two new facilities in Ireland and Germany as part of its global expansion strategy, representing a combined investment of more than €300 million. In Blarney, Ireland, the company has invested €150 million in a life science
Kindeva has officially opened its expanded metered-dose inhaler (MDI) manufacturing facility at Charnwood Campus in Loughborough, marking an investment in sustainable inhalation therapy manufacturing as the industry transitions toward environmentally-friendly propellants. PharmaSource attended the opening ceremony, which featured a comprehensive
Mikart, LLC, a contract development and manufacturing organisation (CDMO), and Nano PharmaSolutions, Inc. (NPS), a nanodrug delivery pharmaceutical company, have reported encouraging interim results from the ongoing Phase 1 clinical trial of NT-301. The proprietary powder nasal spray is being
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
